


CORPORATE PROFILE




OncoCyte is focused on the discovery, development and commercialization of novel non-invasive liquid biopsy diagnostics for the early detection of cancer. Our liquid biopsy diagnostics are being designed to use blood or urine samples and proprietary biomarker algorithms to confirm the absence of cancer.

Current cancer diagnostic standards rely on scans and then invasive surgical tissue sampling procedures to determine if a tumor is benign or malignant. These invasive tests can increase health risks for patients, are time-consuming when time may be of utmost importance, and may still produce indeterminate results leading to both patient anxiety and physician uncertainty about the diagnosis. The cost associated with invasive surgical procedures used for diagnosis also adds to the overall expenditure for the cancer regimen. OncoCyte's liquid biopsy assays provide a potential solution to the healthcare problem of over-diagnosis.



*... potentially malignant, clinician to determine follow up procedure.

OncoCyte's initial focus is on cancers with large patient populations and significant unmet need, including:



STRATEGIC PROFILE

- Positioned to capitalize on standard of care moving to liquid biopsy molecular diagnostics
- Large target markets of up to 14-15M annual patients
- High level of payer and clinician interest due to unmet medical needs and ability to improve economics of cancer care
- First product launch (lung) projected for H1 2017
- Clinical data presented at major meetings with ongoing clinical research and trials at leading scientific institutions


STOCK INFORMATION

NYSE MKT: OCX

Stock Price: \$4.61
(as of March 31st, 2016)


Market Cap: \$117M
(as of March 31st, 2016)

Year-to-date range:
\$2.45 - \$10.24



OncoCyte's pipeline products:

Lung Cancer: OncoCyte's lead product is a confirmatory test intended to improve the decision-making process during lung cancer diagnosis. OncoCyte's diagnostic is being developed as an intermediate step between Low Dose CT screening to find suspicious nodules and downstream procedures to determine if the nodules are malignant. The test is intended to prevent unnecessary tissue biopsies, more effectively identify patients who need invasive procedures and improve health outcomes, while reducing overall lung cancer healthcare costs.



Breast Cancer: OncoCyte's breast cancer diagnostic is being developed as an intermediate step after mammographic screening to reduce the number of patients sent for follow-up tissue biopsies or other imaging procedures. The test is intended to prevent unnecessary tissue biopsies, more effectively identify patients who need invasive procedures, and improve health outcomes.

Bladder Cancer: OncoCyte is currently developing a diagnostic for bladder cancer that could be used in one of three ways: in screening for bladder cancer in patients presenting with hematuria, for confirming indeterminate pathology findings, and for diagnosing recurrence of bladder cancer in patients in remission.



COMPANY LEADERSHIP

WILLIAM ANNETT
Chief Executive Officer

RUSSELL SKIBSTED
Chief Financial Officer

KAREN CHAPMAN
VP Research

LYSSA FRIEDMAN
VP Clinical and Regulatory Affairs

LYNDAL HESTERBERG
VP Development

KRISTINE MECHEM
VP Marketing & Planning

WILLIAM SELTZER
VP Clinical Services

COMPANY CONTACT

MICHAEL POLYVIU
MPolyviou@evcgroup.com

ANALYST COVERAGE

BENCHMARK
Raymond Myers, CFA

JANNEY CAPITAL MARKETS
Paul Knight, CFA

LAKE STREET CAPITAL MARKETS
Bruce D. Jackson